News

Hyperbilirubinemia: Tool Predicts When It's Safe to Stop Therapy

Hyperbilirubinemia: Tool Predicts When It's Safe to Stop Therapy

A new tool could help physicians predict when it is safe to stop phototherapy for newborns with jaundice, according to a study published in Pediatrics. It may also allow some babies to leave the hospital sooner. There are clear guidelines from the American Academy of Pediatrics regarding when physicians should start phototherapy in neonates with hyperbilirubinemia. However, recommendations are less clear on when stop this treatment, explain Dr. Pearl Chang from Seattle Children's Hospital and colleagues.

About Seattle Children’s

Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.